Status:
COMPLETED
Alternate Day Buprenorphine Administration, Phase XII - 17
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of Vermont
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000235
Last Update
August 17 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401